398 related articles for article (PubMed ID: 24201303)
21. Implantable Cardioverter-Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and Complications.
Orgeron GM; James CA; Te Riele A; Tichnell C; Murray B; Bhonsale A; Kamel IR; Zimmerman SL; Judge DP; Crosson J; Tandri H; Calkins H
J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28588093
[TBL] [Abstract][Full Text] [Related]
22. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
[TBL] [Abstract][Full Text] [Related]
23. Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials.
Hess PL; Al-Khatib SM; Han JY; Edwards R; Bardy GH; Bigger JT; Buxton A; Cappato R; Dorian P; Hallstrom A; Kadish AH; Kudenchuk PJ; Lee KL; Mark DB; Moss AJ; Steinman R; Inoue LY; Sanders G
Circ Cardiovasc Qual Outcomes; 2015 Mar; 8(2):179-86. PubMed ID: 25669833
[TBL] [Abstract][Full Text] [Related]
24. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II).
Singh JP; Hall WJ; McNitt S; Wang H; Daubert JP; Zareba W; Ruskin JN; Moss AJ;
J Am Coll Cardiol; 2005 Nov; 46(9):1712-20. PubMed ID: 16256874
[TBL] [Abstract][Full Text] [Related]
25. Denervated Myocardium Is Preferentially Associated With Sudden Cardiac Arrest in Ischemic Cardiomyopathy: A Pilot Competing Risks Analysis of Cause-Specific Mortality.
Fallavollita JA; Dare JD; Carter RL; Baldwa S; Canty JM
Circ Cardiovasc Imaging; 2017 Aug; 10(8):. PubMed ID: 28794139
[TBL] [Abstract][Full Text] [Related]
26. Clinical relevance of slow ventricular tachycardia in heart failure patients with primary prophylactic implantable cardioverter defibrillator indication.
Lüsebrink U; Duncker D; Hess M; Heinrichs I; Gardiwal A; Oswald H; König T; Klein G
Europace; 2013 Jun; 15(6):820-6. PubMed ID: 23325044
[TBL] [Abstract][Full Text] [Related]
27. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?
Ellenbogen KA; Levine JH; Berger RD; Daubert JP; Winters SL; Greenstein E; Shalaby A; Schaechter A; Subacius H; Kadish A;
Circulation; 2006 Feb; 113(6):776-82. PubMed ID: 16461817
[TBL] [Abstract][Full Text] [Related]
28. Long-Term Outcomes Among a Nationwide Cohort of Patients Using an Implantable Cardioverter-Defibrillator: UMBRELLA Study Final Results.
Briongos-Figuero S; García-Alberola A; Rubio J; Segura JM; Rodríguez A; Peinado R; Alzueta J; Martínez-Ferrer JB; Viñolas X; Fernández de la Concha J; Anguera I; Martín M; Cerdá L; Pérez L;
J Am Heart Assoc; 2021 Jan; 10(1):e018108. PubMed ID: 33356406
[TBL] [Abstract][Full Text] [Related]
29. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy.
Vieira AP; Adragão PP; Santos KR; Morgado FB; Cavaco DM; Rossi R; Abecasis M; Neves JP; Bonhosrst D; Gomes JL; Gomes RS
Rev Port Cardiol; 2005 Mar; 24(3):407-15. PubMed ID: 15929624
[TBL] [Abstract][Full Text] [Related]
30. Very high rate programming in primary prevention patients with reduced ejection fraction implanted with a defibrillator: Results from a large multicenter controlled study.
Clementy N; Challal F; Marijon E; Boveda S; Defaye P; Leclercq C; Deharo JC; Sadoul N; Klug D; Piot O; Gras D; Bordachar P; Algalarrondo V; Fauchier L; Babuty D;
Heart Rhythm; 2017 Feb; 14(2):211-217. PubMed ID: 27989789
[TBL] [Abstract][Full Text] [Related]
31. Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator.
Klein HU; Goldenberg I; Moss AJ
Eur Heart J; 2013 Aug; 34(29):2230-42. PubMed ID: 23729691
[TBL] [Abstract][Full Text] [Related]
32. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
[TBL] [Abstract][Full Text] [Related]
33. Age and the Risk of Ventricular Tachyarrhythmia in Patients With an Implantable Cardioverter-Defibrillator.
Aktaş MK; Younis A; Saxena S; Diamond A; Ojo A; Kutyifa V; Steiner H; Steinberg JS; Zareba W; McNitt S; Polonsky B; Rosero SZ; Huang DT; Goldenberg I
JACC Clin Electrophysiol; 2023 Jul; 9(7 Pt 1):979-988. PubMed ID: 36752470
[TBL] [Abstract][Full Text] [Related]
34. Implantable cardioverter defibrillator therapy activation for high risk patients with relatively well preserved left ventricular ejection fraction. Does it really work?
Gatzoulis KA; Tsiachris D; Dilaveris P; Archontakis S; Arsenos P; Vouliotis A; Sideris S; Trantalis G; Kartsagoulis E; Kallikazaros I; Stefanadis C
Int J Cardiol; 2013 Aug; 167(4):1360-5. PubMed ID: 22534047
[TBL] [Abstract][Full Text] [Related]
35. Programming implantable cardioverter-defibrillator therapy zones to high ranges to prevent delivery of inappropriate device therapies in patients with primary prevention: results from the RISSY-ICD (Reduction of Inappropriate ShockS bY InCreaseD zones) trial.
Cay S; Canpolat U; Ucar F; Ozeke O; Ozcan F; Topaloglu S; Aras D
Am J Cardiol; 2015 May; 115(9):1235-43. PubMed ID: 25765588
[TBL] [Abstract][Full Text] [Related]
36. Programming implantable cardioverter-defibrillators in patients with primary prevention indication to prolong time to first shock: results from the PROVIDE study.
Saeed M; Hanna I; Robotis D; Styperek R; Polosajian L; Khan A; Alonso J; Nabutovsky Y; Neason C
J Cardiovasc Electrophysiol; 2014 Jan; 25(1):52-9. PubMed ID: 24112717
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of implantable cardioverter-defibrillators in patients with Chagas disease.
Barbosa MP; da Costa Rocha MO; de Oliveira AB; Lombardi F; Ribeiro AL
Europace; 2013 Jul; 15(7):957-62. PubMed ID: 23376978
[TBL] [Abstract][Full Text] [Related]
38. Impact of accelerated ventricular tachyarrhythmias on mortality in patients with implantable cardioverter-defibrillator therapy.
Schukro C; Leitner L; Siebermair J; Pezawas T; Stix G; Kastner J; Schmidinger H
Int J Cardiol; 2013 Sep; 167(6):3006-10. PubMed ID: 23017814
[TBL] [Abstract][Full Text] [Related]
39. Reduction of the risk of recurring heart failure events with cardiac resynchronization therapy: MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy).
Goldenberg I; Hall WJ; Beck CA; Moss AJ; Barsheshet A; McNitt S; Polonsky S; Brown MW; Zareba W
J Am Coll Cardiol; 2011 Aug; 58(7):729-37. PubMed ID: 21816309
[TBL] [Abstract][Full Text] [Related]
40. Left ventricular lead location and the risk of ventricular arrhythmias in the MADIT-CRT trial.
Kutyifa V; Zareba W; McNitt S; Singh J; Hall WJ; Polonsky S; Goldenberg I; Huang DT; Merkely B; Wang PJ; Moss AJ; Klein H
Eur Heart J; 2013 Jan; 34(3):184-90. PubMed ID: 23053173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
